Metrion Biosciences closes £3.7m new equity financing
Cambridge, UK - Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, announces that it has secured £3.5m in new equity financing, including £2.5m from lead investor Maven Capital Partners (Maven) and £1 million from existing investor, Gresham House Ventures (Gresham House). The funding will be used to further expand Metrion’s laboratories in Cambridge,…
Metrion Biosciences and The KCNC1 Foundation collaborate on development of new ion channel modulators for ultra-rare genetic disorder
Research targeted at identifying novel inhibitors or activators of Kv3.1 mutation
Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the launch of its High Throughput Screening (HTS) capability, as well as the expansion of its state-of-the-art lab and office facil
Metrion Biosciences and Bioqube Ventures collaborate on venture creation project to identify novel ion channel inhibitors for autoimmune diseases
Cambridge, UK and Brussels, Belgium: Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, and Bioqube Ventures, a specialist European life sciences investment firm, announced today that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
Metrion Biosciences expands ion channel drug discovery service capabilities and in-house expertise
Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, announced it has expanded its capabilities and expertise through the addition of automated low volume liquid handling capability and 384-well electrophysiology and fluorescence-based high throughput screening (HTS) assay systems.
Metrion Biosciences appoints Dr Rory Curtis as Vice President US Commercial Operations
Appointment supports the next phase of growth within United States for ion channel contract research and drug discovery services.
Metrion Biosciences expands into new headquarters to support continued growth
Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, today announced that the company has moved to larger, custom designed laboratory and office premises at Granta Park, Cambridge, UK. The new headquarters will allow the company to significantly expand its range of services and cell lines.
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
A new appointment supports international growth within ion channel contract research and drug discovery.
Metrion Biosciences appoints Mark Keogh as Non-Executive Director
Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, today announced the appointment of Mark Keogh as a Non-Executive Director. The appointment follows the Company’s recently announced £2.7m new equity investment led by Gresham House Ventures and is intended to strengthen the Board’s financial and corporate experience, in support of the Company’s…
Metrion Biosciences closes £2.7m new equity financing
Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, today announced that it has secured £2.7m in new equity financing, including £2.25m from lead investor Gresham House Ventures. The funding will be used to expand Metrion’s laboratories in Cambridge, UK, invest in specialist equipment, develop its cell line library, and add GLP cardiac safety services. The…
Metrion Biosciences appoints John Montana as Non-Executive Director
Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, today announced the appointment of John Montana, PhD, as a Non-Executive Director. Expansion of the Board of Directors will support the Company’s further growth as an ion channels focused drug discovery CRO.
Metrion Biosciences and Sosei Heptares agree strategic technology collaboration
Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company and Sosei Group Corporation, the international biopharmaceutical group, announce they will apply Sosei Heptares’ world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration.
Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration
Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.
Metrion Biosciences strengthens global business development team
Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan.
Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicines
Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, announced on 7th April 2020, it has contributed to two new peer-reviewed papers under the US Food and Drug Administration’s (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative.